Concepedia
4
Publications
83
Citations
H-Index
2015
Active since
Affiliations
Novartis (India)(Current)
Weiguang Xue is an author at Novartis (India).
Publications per year
2015–2023
Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective
Stéphane A. Régnier, William Malcolm, Jennifer Haig et al. · ClinicoEconomics and Outcomes Research · 2015 · 28 citations · Full text
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
Min Huang, Peter A. Fasching, Amin Haiderali et al. · Advances in Therapy · 2023 · 24 citations · Full text
<p>A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany</p>
Weiguang Xue, Adam Lloyd, Edel Falla et al. · International Journal of Women s Health · 2019 · 19 citations · Full text
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a <i>MET</i> exon 14 skipping mutation in the United States
Beilei Cai, Zheng‐Yi Zhou, Weiguang Xue et al. · Journal of Medical Economics · 2021 · 12 citations · Full text
Rows per page
1–4 of 4